Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

About 90% of U.S. adults meet the criteria for a newly recognized syndrome that comes from a combination of heart disease, ...

Researchers at the University of Gothenburg have uncovered a critical mechanism that may pave the way for innovative ...

Investigators compared the outcomes of patients with type 2 diabetes who continued versus stopped metformin after progressing to stage 4 chronic kidney disease.

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...

Five regions in the U.S. have been selected to implement a new preventive health initiative to improve care for people with a cluster of chronic conditions known as cardiovascular-kidney-metabolic ...

Researchers at the University of Gothenburg, Sweden, have uncovered a critical mechanism that may pave the way for innovative ...

A new study suggests that the benefits of prescribing anticoagulation drugs to certain older people outweigh the potential risks.

Obinutuzumab B-cell depleting therapy is more effective than standard care in treating patients with active proliferative lupus nephritis.